Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Cancer Therapies02:49

Cancer Therapies

7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Tumor Immunotherapy01:27

Tumor Immunotherapy

524
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
524

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Case Report: Prolonged response to cabozantinib and pembrolizumab in treatment-refractory metastatic pancreatic ductal adenocarcinoma.

Frontiers in oncology·2026
Same author

Toward Safer Floxuridine Dosing in an Era of Resurgent Hepatic Artery Infusion Pump Chemotherapy.

Annals of surgical oncology·2025
Same author

Embryology of the Vascular System: Implications for Variants.

Seminars in interventional radiology·2025
Same author

Understanding Portosystemic Collateral Anatomy.

Seminars in interventional radiology·2025
Same author

Anatomy Insights and Key Pearls for Bronchial Artery Embolization.

Seminars in interventional radiology·2025
Same author

Anatomical Considerations for Biliary Interventions: Navigating Challenging Cases.

Seminars in interventional radiology·2025

Related Experiment Video

Updated: Jun 30, 2025

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
00:06

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

8.9K

Hepatocellular Carcinoma: Advances in Systemic Therapy.

Insija Ilyas Selene1, Merve Ozen2, Reema A Patel2

  • 1Department of Medical Oncology, University of Kentucky College of Medicine, Lexington, Kentucky.

Seminars in Interventional Radiology
|March 18, 2024
PubMed
Summary

Systemic therapies for advanced hepatocellular carcinoma (HCC) are evolving. Immunotherapy combinations like atezolizumab/bevacizumab show improved outcomes, shifting treatment paradigms beyond traditional targeted therapies.

Keywords:
HCCchemotherapyinterventional radiologyliver cancersystemic therapy

More Related Videos

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.2K
Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

752

Related Experiment Videos

Last Updated: Jun 30, 2025

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
00:06

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

8.9K
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.2K
Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

752

Area of Science:

  • Hepatology
  • Medical Oncology
  • Cancer Research

Background:

  • Hepatocellular carcinoma (HCC) is a leading cause of cancer death globally.
  • Advanced HCC treatment historically relied on molecular targeted therapies, with sorafenib as a long-standing standard.

Purpose of the Study:

  • To review the current landscape of systemic therapies for advanced HCC.
  • To highlight recent advancements and their impact on patient outcomes.

Main Methods:

  • Review of recent clinical trials and FDA-approved treatments for advanced HCC.
  • Analysis of emerging immunotherapy combinations and targeted therapies.

Main Results:

  • Atezolizumab and bevacizumab combination demonstrates superior outcomes compared to sorafenib.
  • Tremelimumab and durvalumab combination shows efficacy in phase III trials.
  • Immunotherapy combinations are emerging as key first-line treatments.

Conclusions:

  • Systemic therapy for advanced HCC has shifted towards immunotherapy combinations.
  • Treatment decisions require consideration of patient-specific factors and disease etiology.
  • Optimizing systemic and local-regional therapies is crucial for improved HCC patient outcomes.